No Data
No Data
No Data
Medinet - (Status of Disclosure) Taiwan regulatory authorities have approved the provision of gamma-delta T-cell therapy in new medical facilities.
On the 8th, Medinet announced that the Taiwan regulatory authority has approved the provision of gamma delta T cell therapy in new medical institutions.
Medinet: Financial results briefing materials for the 2nd quarter of the fiscal year ending 2024/9
Medinet: Confirmation letter
Medinet: Quarterly Report - 29th Quarter 2nd Quarter (2024/01/01 to 2024/03/31)
MDNT -- recording of non-operating income and non-operating expenses
Medinet <2370> announced on the 10th the recording of non-operating income and non-operating expenses for the 2nd quarter cumulative period (2023/10/2024/3) of the fiscal year ending 2024/9. As for non-operating income, investment business union management profit of 20 million yen was recorded as non-operating income, and processing interruption income of 0.04 billion yen billed to customers when contract manufacturing of specific cell processed products was interrupted was recorded as non-operating income. Also, collect part of long-term loans, etc. for which provision for debt loss has been recorded
Medinet--2Q also increased sales by 2 digits, and sales in the specific cell processed products manufacturing industry and CDMO business increased
Medinet <2370> announced financial results for the 2nd quarter (23/10/24 to 3/24) of the fiscal year ending 2024/9 on the 10th. Net sales increased 14.4% from the same period last year to 399 million yen, operating loss was 658 million yen (loss of 671 million yen in the same period last year), ordinary loss was 632 million yen (loss of 669 million yen), and quarterly net loss was 634 million yen (loss of 676 million yen). Cell processing sales increased 14.4% from the same period last year to 399 million yen, and segment loss was 154 million yen
No Data